

12 April 2017

Evidence Building for the Application of HepaFat-Scan in the Clinical Community

Resonance Health (ASX:RHT) is pleased to provide an update on two of its studies being run in partnership with global key opinion leaders to collect further evidence promoting clinical uptake of the Company's HepaFat-Scan® technology. The collected data will also support the inclusion of HepaFat-Scan in clinical guidelines for the routine care of patients. HepaFat-Scan provides a non-invasive, regulatory-cleared, accurate measurement of volumetric liver fat fraction (VLFF) and has the potential to provide clinical benefits in a number of highly prevalent disease indications worldwide, including; non-alcoholic fatty liver disease (NAFLD), diabetes and metabolic disease, liver and bariatric surgeries, and in combination with FerriScan®, unexplained hyperferritinaemia. The final HepaFat-Scan analyses for a paediatric NAFLD validation study have recently been completed and participation in a prominent Western Australian population study, the Raine study, is well underway, with over 200 analyses performed to date.

Paediatric Non-Alcoholic Fatty Liver Disease Study Completion

The validation study of HepaFat-Scan in a paediatric patient population with NAFLD is a collaboration with Emory University and the prestigious Children's Healthcare of Atlanta, USA. NAFLD is an obesity-related liver disease which has the potential to damage the liver and develop into more serious complications such as inflammation, fibrosis, cirrhosis and cancer. Fatty liver disease is a major healthcare burden globally and its prevalence is predicted to increase with the global obesity epidemic. It is expected that 50% of adults in the US will be obese by 2030.

The study aim was to independently validate HepaFat-Scan in a new patient cohort against alternative techniques for the assessment of liver fat including liver biopsy and magnetic resonance spectroscopy (MRS). Resonance Health's Clinical Manager, Dr Sherif Boulos commented:

"HepaFat-Scan has substantial advantages over both liver biopsy and MRS, both in terms of its accuracy, ease of use, and patient safety. Although the current gold standard for assessing liver fat is via liver biopsy; this technique is invasive, painful, and lacks sensitivity due to its subjective nature. Conversely, while MRS is both an accurate and non-invasive test, it is very time-consuming, technically challenging, and not recommended for routine clinical use. We eagerly await the publication of findings from this important study; as positive results will support the use of HepaFat-Scan as a technique to assist clinicians in the diagnosis and treatment of patients."

Now that the HepaFat-Scan analyses for the study have been completed, the team at Emory University and the Children's Healthcare of Atlanta are currently analysing the results in preparation for publication.

The Western Australian Raine Study

Resonance Health is proudly participating in the Western Australian Raine Study with the provision of HepaFat-Scan. The Western Australian Pregnancy Cohort (Raine) Study was established between 1989 and 1991 to allow unique and valuable information collection and investigation into the health of a general population. A total of 2868 participants were enrolled at birth and regular follow ups are still performed. This renowned study is considered one of the largest successful studies of its kind and involves collaboration with over 150 researchers worldwide.

The current study which commenced in 2016 is a follow up of participants at age 27 and has a focus on cardiovascular health and internal fat. The provision of HepaFat-Scan to the study participants will allow the collection of valuable information on the percentage of fat in the liver in a general population and the potential relationship between liver fat and health complications. This well recognised study will raise the profile of HepaFat-Scan and is anticipated to further the clinical uptake of HepaFat-Scan in the diagnosis and monitoring of fatty liver disease.

Resonance Health is proud to be collaborating with such highly respected studies and medical experts in the field of fatty liver disease. The results of these studies, together with published scientific papers, will help to promote and build on the existing use of HepaFat-Scan in the clinical community. The Company will continue to update stakeholders as the benefits of these studies come to fruition.

For further information please contact:

Sander Bangma

General Manager, Resonance Health

E: SanderB@resonancehealth.com P: +61 (0)8 9286 5300